Here are three things to know.
- Tremfya is the only approved biologic drug that targets a specific protein secreted by cells that plays a main role in plaque psoriasis.
- Psoriasis patients receive Tremfya as an injection every eight weeks, with a dose administered at the first and fourth week to start.
- In a recent clinical trial, more than 7 out of 10 patients taking Tremfya had 90 percent clearer skin at week 24, compared to 4 out of 10 patients taking AbbVie’s rival drug Humira.
More articles on supply chain:
7 must-reads for supply chain leaders this week
Amgen leukemia drug earns full FDA approval after successful clinical trial
House passes FDA user fee reauthorization bill
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.